Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug Derived From Sea Squirt Shows Potent Anti-tumour Activity

21.06.2007
The sea-squirt derived drug trabectedin (ecteinascidinin-743) shows anti-tumour activity in more than half of patients with a specific type of cancer, conclude authors of an Article published early Online and in the July edition of The Lancet Oncology.

Dr Federica Grosso, Sarcoma Unit, Instituto Nazionale Tumori, Milan, Italy, and colleagues in sarcoma centres in Boston, London, Lyon and Paris, did a retrospective study of the effect of trabectedin (derived from Ecteinascidia Turbinata) on patients with advanced pre-treated myxoid liposarcomas, a subtype of the liposarcoma group of cancers associated with specific chromosomal mutations.

They found that of 51 patients with myxoid liposarcomas given trabectedin as part of a compassionate-use programme, two saw their tumours disappear completely (complete response) while a further 24 saw the longest diameter of their tumour shrink by at least 30% (partial response), representing an overall response rate of 51%. Previous studies of trabectedin have shown response rates no higher than 20%. Of these 26 patients that responded, 23 had undergone radiological review of their tumours. The authors showed 17 of these 23 had also experienced reduced tumour density prior to the shrinkage or disappearance of their tumour.

In addition, the progression free-survival rate at six months was 88%, whereas previous studies in all soft tissue sarcomas have placed this figure closer to 20%. Median progression-free survival was 14 months.

The authors say: “If the results of this analysis are reproduced in ongoing prospective studies, myxoid sarcoma would represent a uniquely sensitive subgroup to trabectedin treatment in the heterogeneous family of soft-tissue sarcoma.”

Surgical removal is the mainstay of current treatment regimens for soft-tissue sarcoma, but despite this around half of patients develop distant metastases (secondary tumours) and die. Certain drugs, such as anthracyclines and ifosfamide, have shown response rates of 20-40%, but new drugs are needed.

The authors say that a compassionate-use programme of trabectedin treatment remains ongoing. They conclude: “This analysis has resulted in the initiation of two prospective studies to assess the role of trabectedin in the treatment of myxoid liposarcoma in the pre-operative and metastatic settings. Furthermore, the selective mechanism of action for trabectedin in this translocation-related sarcoma is being studied.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>